BridgeBio Collaborates with Helsinn to Co- Develop and Commercialize Infigratinib in Oncology

Shots:

• BridgeBio to receive ~$2.45B+ including ~$100M in up front, regulatory and commercial milestones along with royalties on net sales of Infigratinib from Helsinn Group. The agreement is expected to close in Q2’21
• Helsinn to co-commercialize infigratinib in oncology and other indications except for skeletal dysplasia indications in the US and will equally share profits and losses. Additionally, BridgeBio will retain all rights in skeletal dysplasia including achondroplasia
• Helsinn will lead and have exclusive commercialization rights for infigratinib in non-skeletal dysplasia indications outside the US excluding China, Hong Kong, and Macau. Additionally, the FDA is reviewing an NDA for infigratinib to treat patients with previously treated, FGFR-mutant cholangiocarcinoma

Click here to­ read full press release/ article | Ref: BridgeBio | Image: PRNewswire